Mumbai: The World Health Organization (WHO) has approved the Emergency Use List (EUL) for Covaxin, a COVID-19 vaccine from Hyderabad-based Bharat Biotech.
Earlier, a WHO panel had sought additional clarification from the manufacturer of Covaxin to conduct a final EUL risk-benefit assessment for global use of the vaccine.
The approval was made on the recommendation of the Technical Advisory Group (TAG) for Emergency Use Listing (TAG-EUL), an independent advisory panel to WHO for listing a Covid19 vaccine for emergency use under the EUL process.
https://twitter.com/ANI/status/1455871105315446788?s=20
Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.
Bharat Biotech said it has concluded the final analysis of Covaxin efficacy from Phase III trials. Bharat Biotech’s Covaxin and AstraZeneca and Serum Institute’s Covishield are the two widely used vaccines in India.
Meanwhile, India’s cumulative vaccination coverage crossed 107 crores. The WHO has so far approved Covid-19 vaccines of Pfizer-BioNTech, AstraZeneca-SK Bio/Serum Institute of India, Johnson 7 Johnson – Janssen, Moderna, and Sinopharm for emergency use.
Follow us on Twitter, Instagram, and like us on Facebook for the latest updates and interesting stories.
